CD122抗体—艾普蒂 新品

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Flow cytometric analysis of HL-60 cells using CD122 mouse mAb (green) and negative control (red).    

  
  

•  

   

     Flow cytometric analysis of Jurkat cells using CD122 mouse mAb (green) and negative control (red).    

  
  

CD122. also known as interleukin-2 receptor beta (IL-2Rβ), is a subunit of the IL-2 receptor complex expressed on immune cells, including T cells, B cells, and natural killer (NK) cells. It pairs with the common gamma chain (γc, CD132) to form a functional receptor for IL-2 and IL-15. cytokines critical for lymphocyte activation, proliferation, and homeostasis. CD122 is particularly important in regulating effector and memory T cell responses, as well as NK cell function.

CD122-targeting antibodies are designed to modulate immune activity by either blocking or activating this receptor pathway. In therapeutic contexts, antagonistic anti-CD122 antibodies have been explored to suppress excessive immune activation in autoimmune diseases or organ transplantation by interfering with IL-2/IL-15 signaling. Conversely, agonistic antibodies may enhance antitumor immunity by promoting T cell or NK cell activity, potentially synergizing with checkpoint inhibitors.

Research applications of CD122 antibodies include flow cytometry for immune cell profiling, functional studies of IL-2/IL-15 pathways, and preclinical models of cancer or autoimmunity. Challenges in targeting CD122 involve balancing its dual roles in pro-inflammatory and regulatory immune subsets (e.g., effector T cells vs. Tregs). Recent studies also investigate its combination with cytokine therapies to optimize specificity and reduce systemic toxicity.